Ambreen Aziz

Title: Ambreen Aziz: Innovator in Aromatase Inhibitor Research

Introduction

Ambreen Aziz is a prominent inventor based in Karachi, Pakistan. She has made significant contributions to the field of cancer research, particularly in the development of aromatase inhibitors for the treatment of estrogen receptor-positive (ER+) breast cancer. Her innovative work has the potential to impact the lives of many patients battling this disease.

Latest Patents

Ambreen Aziz holds a patent for the "Synthesis of a potent aromatase inhibitor 17α-acetoxy-10β,11β-dihydroxy-progesterone for the treatment of ER+ breast cancer." This patent describes the biotransformation of gestonorone acetate, which yielded a new analogue, 17α-acetoxy-10β,11β-dihydroxy-progesterone. This compound has been identified as a non-cytotoxic inhibitor of the human aromatase enzyme, with an inhibitory concentration (IC) of 0.827±0.066 μM. Notably, this compound demonstrated significant aromatase inhibitory activity compared to the standard drug exemestane, which has an IC of 0.232±0.03 μM.

Career Highlights

Ambreen Aziz's career is marked by her dedication to advancing cancer treatment through innovative research. Her work on aromatase inhibitors showcases her expertise in biochemistry and pharmacology. She has successfully developed a compound that not only inhibits aromatase but also shows promise in being less toxic to human cells.

Collaborations

Ambreen has collaborated with notable researchers in her field, including Muhammad Iqbal Choudhary and Atia-tul-Wahab. These collaborations have enriched her research and contributed to the advancement of knowledge in cancer therapeutics.

Conclusion

Ambreen Aziz is a trailblazer in the field of aromatase inhibitor research, with her innovative patent offering hope for improved treatments for ER+ breast cancer. Her contributions to science and medicine are commendable and reflect her commitment to enhancing patient care through research.